Skip to main content
. 2013 Jul 31;305(8):C867–C876. doi: 10.1152/ajpcell.00121.2013

Fig. 4.

Fig. 4.

TGF-β1 reduces the effect of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors. Typical current recordings of vehicle or TGF-β1-treated (5 ng/ml, 24 h) PVD9902 monolayers exposed sequentially to forskolin (2 μM) followed by DASU-02 (A; 100 μM) or GlyH-101 (B; 10 μM). C: summarized results of CFTR inhibitor blocked anion secretion from 5–6 paired experiments. *P < 0.05, statistical difference from vehicle.